Abstract
In recent years, preparations based on lactic acid bacteria have proven to be effective in the complex therapy of infectious diseases. Despite the large number of positive results of the use of these preparations and their widespread use, there are some risks associated with their use. To minimize these risks, it is necessary to regulate the production, sale, and use of probiotic preparations on an equal basis with medicines. To date, there are no made-in-Kazakhstan probiotic preparations with clinically proven safety and performance in the pharmaceutical market of Kazakhstan. The purpose of this paper was to present preclinical trials of this preparation confirming its safety and medical performance and demonstrate the readiness for clinical trials of the Kazakh probiotic medication AS-Probionorm. The AS-Probionorm probiotic medication developed by us based on an association of specific action lactic acid bacteria (Lactobacillus fermentum 30 and Lactobacillus cellobiosus 36), has high antimicrobial activity against pathogens of intestinal diseases. This study introduces AS-Probionorm as the first locally produced probiotic in Kazakhstan with clinically established safety and effectiveness, marking a significant step forward in the national production of biomedical health solutions.